幽门螺杆菌小鼠和人类免疫蛋白质组的比较验证了用于抗原筛选的临床前小鼠感染模型。
A comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening.
作者信息
Bumann Dirk, Holland Petra, Siejak Frank, Koesling Jan, Sabarth Nicolas, Lamer Stefanie, Zimny-Arndt Ursula, Jungblut Peter R, Meyer Thomas F
机构信息
Department of Molecular Biology, Max-Planck-Institute for Infection Biology, Berlin, Germany.
出版信息
Infect Immun. 2002 Nov;70(11):6494-8. doi: 10.1128/IAI.70.11.6494-6498.2002.
Abstract
Preclinical mouse infection models are widely used for Helicobacter vaccine development, but how well such models mimic important aspects of human infections is unknown. A comparison of Helicobacter pylori immunoproteomes of infected mice with previously reported patient data reveals a high agreement in the antigens recognized, suggesting that H. pylori in vivo protein composition and recognition by the host immune system are comparable in mice and humans. Murine Helicobacter models may thus be valid to screen antigens for human vaccination.
摘要
临床前小鼠感染模型广泛用于幽门螺杆菌疫苗的研发，但此类模型对人类感染重要方面的模拟程度尚不清楚。将感染小鼠的幽门螺杆菌免疫蛋白质组与先前报道的患者数据进行比较，结果显示在识别出的抗原方面高度一致，这表明小鼠和人类体内幽门螺杆菌的蛋白质组成以及宿主免疫系统对其的识别具有可比性。因此，小鼠幽门螺杆菌模型可能适用于筛选人类疫苗的抗原。
相似文献
1
A comparison of murine and human immunoproteomes of Helicobacter pylori validates the preclinical murine infection model for antigen screening.
Infect Immun. 2002 Nov;70(11):6494-8. doi: 10.1128/IAI.70.11.6494-6498.2002.
2
Multiparameter selection of Helicobacter pylori antigens identifies two novel antigens with high protective efficacy.
Infect Immun. 2002 Nov;70(11):6499-503. doi: 10.1128/IAI.70.11.6499-6503.2002.
3
Protection against Helicobacter pylori infection by intestinal immunisation with a 50/52-kDa subunit protein.
FEMS Immunol Med Microbiol. 1999 Jun;24(2):221-5. doi: 10.1111/j.1574-695X.1999.tb01286.x.
4
A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori.
Vaccine. 2011 Feb 1;29(6):1235-41. doi: 10.1016/j.vaccine.2010.11.088. Epub 2010 Dec 13.
5
Catalase, a novel antigen for Helicobacter pylori vaccination.
Infect Immun. 1997 Nov;65(11):4668-74. doi: 10.1128/iai.65.11.4668-4674.1997.
6
Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.
Int J Med Microbiol. 2008 Jan;298(1-2):151-9. doi: 10.1016/j.ijmm.2007.07.006. Epub 2007 Aug 21.
7
The C-terminally encoded, MHC class II-restricted T cell antigenicity of the Helicobacter pylori virulence factor CagA promotes gastric preneoplasia.
J Immunol. 2011 Jun 1;186(11):6165-72. doi: 10.4049/jimmunol.1003472. Epub 2011 Apr 25.
8
[A vaccine against Helicobacter pylori infection].
Lijec Vjesn. 2002 Sep;124 Suppl 1:79-82.
9
Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils.
Helicobacter. 2017 Dec;22(6). doi: 10.1111/hel.12428. Epub 2017 Aug 29.
10
Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.
Helicobacter. 2006 Apr;11(2):113-22. doi: 10.1111/j.1523-5378.2006.00385.x.
引用本文的文献
1
A Mouse Model of Helicobacter pylori Infection.
Methods Mol Biol. 2021;2283:131-151. doi: 10.1007/978-1-0716-1302-3_14.
2
Growth phase-dependent composition of the Helicobacter pylori exoproteome.
J Proteomics. 2016 Jan 1;130:94-107. doi: 10.1016/j.jprot.2015.08.025. Epub 2015 Sep 9.
3
Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forward.
Front Immunol. 2014 Oct 27;5:516. doi: 10.3389/fimmu.2014.00516. eCollection 2014.
4
Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV).
PLoS One. 2010 Nov 9;5(11):e13915. doi: 10.1371/journal.pone.0013915.
5
Challenge model for Helicobacter pylori infection in human volunteers.
Gut. 2004 Sep;53(9):1235-43. doi: 10.1136/gut.2003.037499.
本文引用的文献
1
Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori.
Infect Immun. 2002 Jul;70(7):3396-403. doi: 10.1128/IAI.70.7.3396-3403.2002.
2
Identification of surface proteins of Helicobacter pylori by selective biotinylation, affinity purification, and two-dimensional gel electrophoresis.
J Biol Chem. 2002 Aug 2;277(31):27896-902. doi: 10.1074/jbc.M204473200. Epub 2002 May 22.
3
Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6573-8. doi: 10.1073/pnas.092569199. Epub 2002 May 7.
4
Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis.
Proteomics. 2002 May;2(5):580-90. doi: 10.1002/1615-9861(200205)2:5<580::AID-PROT580>3.0.CO;2-G.
5
Immunoproteomics of Helicobacter pylori infection and relation to gastric disease.
Proteomics. 2002 Mar;2(3):313-24. doi: 10.1002/1615-9861(200203)2:3<313::aid-prot313>3.0.co;2-7.
6
Heterogeneity of Helicobacter pylori cag genotypes in experimentally infected mice.
FEMS Microbiol Lett. 2001 Sep 11;203(1):109-14. doi: 10.1111/j.1574-6968.2001.tb10828.x.
7
Assessment of Helicobacter pylori gene expression within mouse and human gastric mucosae by real-time reverse transcriptase PCR.
Infect Immun. 2001 Aug;69(8):4759-66. doi: 10.1128/IAI.69.8.4759-4766.2001.
8
IVIAT: a novel method to identify microbial genes expressed specifically during human infections.
Trends Microbiol. 2000 Jul;8(7):336-9. doi: 10.1016/s0966-842x(00)01775-3.
9
Comparative proteome analysis of Helicobacter pylori.
Mol Microbiol. 2000 May;36(3):710-25. doi: 10.1046/j.1365-2958.2000.01896.x.
10
Gastric mucosa-associated lymphoid tissue lymphoma: implications of animal models on pathogenic and therapeutic considerations--mouse models of gastric lymphoma.
Recent Results Cancer Res. 2000;156:42-51. doi: 10.1007/978-3-642-57054-4_6.
Zotero 插件